Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 5
2005 1
2006 1
2007 7
2008 5
2011 1
2012 1
2013 2
2016 1
2017 5
2018 3
2019 6
2020 4
2021 4
2022 12
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Results by year

Filters applied: . Clear all
Page 1
Medical Treatment of Female Sexual Dysfunction.
Nappi RE, Tiranini L, Martini E, Bosoni D, Righi A, Cucinella L. Nappi RE, et al. Urol Clin North Am. 2022 May;49(2):299-307. doi: 10.1016/j.ucl.2022.02.001. Urol Clin North Am. 2022. PMID: 35428435 Review.
Health care providers can screen for FSD according to their level of expertise and deliver at least basic counseling before eventually referring to sexual medicine specialists for specific care. The therapeutic algorithm comprises a multidisciplinary approach, including ph …
Health care providers can screen for FSD according to their level of expertise and deliver at least basic counseling before eventually refer …
Bremelanotide: First Approval.
Dhillon S, Keam SJ. Dhillon S, et al. Drugs. 2019 Sep;79(14):1599-1606. doi: 10.1007/s40265-019-01187-w. Drugs. 2019. PMID: 31429064 Review.
Bremelanotide (Vyleesi) is a melanocortin receptor agonist recently approved in the USA for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), as characterized by low sexual desire that causes marked distress or interp …
Bremelanotide (Vyleesi) is a melanocortin receptor agonist recently approved in the USA for the treatment of premenopausal women with …
An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder.
Cipriani S, Alfaroli C, Maseroli E, Vignozzi L. Cipriani S, et al. Expert Opin Pharmacother. 2023 Jan;24(1):15-21. doi: 10.1080/14656566.2022.2132144. Epub 2022 Oct 18. Expert Opin Pharmacother. 2023. PMID: 36242769 Review.
AREAS COVERED: Hereby we summarize bremelanotide's proposed mechanism of action, pharmacokinetics, efficacy and safety data derived from clinical trials. A literature search of peer-reviewed publications on the current evidence on the pharmacotherapy with bremelanotide …
AREAS COVERED: Hereby we summarize bremelanotide's proposed mechanism of action, pharmacokinetics, efficacy and safety data derived f …
Safety Profile of Bremelanotide Across the Clinical Development Program.
Clayton AH, Kingsberg SA, Portman D, Sadiq A, Krop J, Jordan R, Lucas J, Simon JA. Clayton AH, et al. J Womens Health (Larchmt). 2022 Feb;31(2):171-182. doi: 10.1089/jwh.2021.0191. J Womens Health (Larchmt). 2022. PMID: 35147466 Clinical Trial.
Methods: Review of bremelanotide's safety profile from the clinical development program (phases 1 through 3). ...Conclusions: The AEs associated with bremelanotide are mostly mild to moderate. Although not deemed clinically important, bremelanotide should be …
Methods: Review of bremelanotide's safety profile from the clinical development program (phases 1 through 3). ...Conclusions: The AEs …
The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women.
Pfaus JG, Sadiq A, Spana C, Clayton AH. Pfaus JG, et al. CNS Spectr. 2022 Jun;27(3):281-289. doi: 10.1017/S109285292100002X. Epub 2021 Jan 18. CNS Spectr. 2022. PMID: 33455598 Review.
MCRs are found throughout the body, including the brain. Bremelanotide is an MCR agonist that nonselectively activates several of the receptor subtypes, of which subtype 4 (MC4R) is the most relevant at therapeutic doses. ...This review presents what is known about …
MCRs are found throughout the body, including the brain. Bremelanotide is an MCR agonist that nonselectively activates several of the …
Bremelanotide and flibanserin for low sexual desire in women: the fallacy of regulatory precedent.
Mintzes B, Tiefer L, Cosgrove L. Mintzes B, et al. Drug Ther Bull. 2021 Dec;59(12):185-188. doi: 10.1136/dtb.2021.000020. Epub 2021 Oct 12. Drug Ther Bull. 2021. PMID: 34642243 Review.
The US Food and Drug Administration (FDA) has approved two drugs for 'hypoactive sexual desire disorder' in women, flibanserin (Addyi) in 2015 and bremelanotide (Vyleesi) in 2019. In this paper we examine the outcome measures and clinical trial data upon which regulatory a …
The US Food and Drug Administration (FDA) has approved two drugs for 'hypoactive sexual desire disorder' in women, flibanserin (Addyi) in 20 …
Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder.
Mayer D, Lynch SE. Mayer D, et al. Ann Pharmacother. 2020 Jul;54(7):684-690. doi: 10.1177/1060028019899152. Epub 2020 Jan 1. Ann Pharmacother. 2020. PMID: 31893927
Data Sources: Literature search of Medline, SCOPUS, and EMBASE was performed using the search terms bremelanotide, bremelanotide injection, Vyleesi, and melanocortin 4 receptor agonist between January 1, 1996, and December 15, 2019. ...Bremelanotide's place i …
Data Sources: Literature search of Medline, SCOPUS, and EMBASE was performed using the search terms bremelanotide, bremelanotide …
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.
Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Simon JA. Kingsberg SA, et al. Obstet Gynecol. 2019 Nov;134(5):899-908. doi: 10.1097/AOG.0000000000003500. Obstet Gynecol. 2019. PMID: 31599840 Free PMC article. Clinical Trial.
OBJECTIVE: To evaluate the safety and efficacy of bremelanotide for the treatment of premenopausal women with hypoactive sexual desire disorder. ...Patients taking bremelanotide experienced more nausea, flushing, and headache (10% or more in both studies) compared w …
OBJECTIVE: To evaluate the safety and efficacy of bremelanotide for the treatment of premenopausal women with hypoactive sexual desir …
Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide.
Simon JA, Kingsberg SA, Portman D, Jordan R, Lucas J, Sadiq A, Krop J, Clayton AH. Simon JA, et al. J Womens Health (Larchmt). 2022 Mar;31(3):391-400. doi: 10.1089/jwh.2021.0225. Epub 2022 Feb 25. J Womens Health (Larchmt). 2022. PMID: 35230162 Clinical Trial.
This report investigates efficacy of bremelanotide versus placebo according to prespecified subgroups (age, weight, body mass index [BMI], and bioavailable testosterone) in the RECONNECT studies. Materials and Methods: Patients self-administered bremelanotide 1.75 m …
This report investigates efficacy of bremelanotide versus placebo according to prespecified subgroups (age, weight, body mass index [ …
58 results